Literature DB >> 17183572

Current status of newborn screening: decision-making about the conditions to include in screening programs.

Michael S Watson1.   

Abstract

Newborn screening is considered a highly successful public health program that has resulted in the reduction of mortality, mental retardation, and other serious disabilities in thousands of children since the introduction of screening for phenylketonuria (PKU) in the 1960s. Programs are based in state public health departments such that each state independently reaches decisions as to which conditions should be mandated for inclusion in programs, leading to considerable variability among the states as to what is being screened. New technologies and knowledge of the genetics of many conditions have greatly expanded the number of conditions with potential for inclusion in newborn screening. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 17183572     DOI: 10.1002/mrdd.20127

Source DB:  PubMed          Journal:  Ment Retard Dev Disabil Res Rev        ISSN: 1080-4013


  2 in total

1.  Successful Implementation of Expanded Newborn Screening in the Philippines Using Tandem Mass Spectrometry.

Authors:  Carmencita D Padilla; Bradford L Therrell; Maria Melanie Liberty B Alcausin; Mary Anne D Chiong; Mary Ann R Abacan; Ma Elouisa L Reyes; Charity M Jomento; Maria Truda T Dizon-Escoreal; Margarita Aziza E Canlas; Michelle E Abadingo; J Edgar Winston C Posecion; Conchita G Abarquez; Alma P Andal; Anna Lea G Elizaga; Bernadette C Halili-Mendoza; Maria Paz Virginia K Otayza; David S Millington
Journal:  Int J Neonatal Screen       Date:  2022-01-19

2.  Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies.

Authors:  Katrina A B Goddard; Evelyn P Whitlock; Jonathan S Berg; Marc S Williams; Elizabeth M Webber; Jennifer A Webster; Jennifer S Lin; Kasmintan A Schrader; Doug Campos-Outcalt; Kenneth Offit; Heather Spencer Feigelson; Celine Hollombe
Journal:  Genet Med       Date:  2013-04-04       Impact factor: 8.822

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.